Obesity evidence dossier
Bofanglutide
Investigational extended-interval injectable GLP-1RA with substantial Phase 2b weight-loss evidence; confirmatory Phase 3 obesity evidence is pending.
Total weight loss
18.5%
GRADUAL-1 · 48 mg every two weeks · week 52 · Analysis not fully specified
Placebo-adjusted
17.4%
Difference from placebo in the same study when reported.
Study context
Long-acting human GLP-1 receptor agonist with a 22-carbon fatty-diacid moiety./Adults with obesity or overweight in China; diabetes exclusion not specified in this source/640 participants across the study/52-week endpoint
Baseline: See the source for enrollment criteria
Ranked result & calculation
GRADUAL-1 · 48 mg every two weeks · 52 weeks
Adults with obesity or overweight in China; diabetes exclusion not specified in this source. 640 participants across the study (not this dose arm alone).
Analysis not fully specified. The source does not establish a treatment-policy analysis; interpret this score provisionally. Modified intention-to-treat analysis; discontinuation handling is not specified. Separate US per-protocol results are not used.
- Average weight loss
- 18.54%
- Placebo group
- 1.11% loss
- Beyond placebo
- 17.43 percentage points (arm subtraction)
- Stopped due to adverse events
- Not verified for this result
Score: 70% × 76.2 total-loss points + 30% × 80.7 beyond-placebo points = 78/100, rounded. Conversion scales
Gan & Lee, GRADUAL-1 ↗Phase 3 · Sponsor disclosure · Reviewed 2026-09-21
Evidence
Benchmark read
GRADUAL-1: Analysis not fully specified. Modified intention-to-treat analysis; discontinuation handling is not specified. Separate US per-protocol results are not used.
Safety
Side effects and cautions
Discontinuation read
Adverse-event discontinuation has not been verified for this result.
Common side effects
Mostly grade 1–2 gastrointestinal adverse events, particularly nausea, vomiting, and diarrhea; injection-site reactions also occurred.
Main cautions
Not approved for weight management. High-dose groups had more treatment discontinuations, and Phase 2b evidence was limited to a Chinese population and 30 weeks.
Upcoming catalyst
What to watch next
BALANCE-OBS Phase 3 initiation and eventual 36-week comparative results.
Linked clinical trials
Trials in the saddl3 obesity snapshot
Non-diabetic obesity studies are prioritized; diabetes and healthy-volunteer studies remain visible and labeled.
NCT06728124
Phase 3
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Obese/Overweight Subjects
Gan & Lee Pharmaceuticals.
Non-diabetic obesity
Nov 25, 2025
NCT07150975
Phase 3
Phase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
Gan & Lee Pharmaceuticals.
Non-diabetic obesity
Nov 25, 2025
NCT06737042
Phase 2
Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants
Gan and Lee Pharmaceuticals, USA
Non-diabetic obesity
Feb 4, 2025
NCT06256562
Phase 2
A Study of GZR18 Injection in Obese/Overweight Patients
Gan and Lee Pharmaceuticals, USA
Non-diabetic obesity
Oct 1, 2025
NCT06256536
Phase 2
A Study of GZR18 Injection in Chinese Obese/Overweight Patients
Gan and Lee Pharmaceuticals, USA
Non-diabetic obesity
Feb 23, 2024
NCT06670209
Phase 1
A Phase I Clinical Study to Evaluate the Effect of GZR18 Injection on the Pharmacokinetics of Oral Metformin Hydrochloride Tablets in Overweight/Obese Subjects
Gan and Lee Pharmaceuticals, USA
Non-diabetic obesity
Nov 1, 2024
NCT06548945
Phase 1
A Phase I Study of GZR18 Injection in Obese/Overweight Subjects
Gan and Lee Pharmaceuticals, USA
Non-diabetic obesity
Aug 14, 2024
NCT07292441
Phase 3
Extension Study of the Phase 3 Clinical Study of GZR18 Injection for Weight Loss
Gan & Lee Pharmaceuticals.
Other obesity study
Mar 11, 2026
NCT06548997
Phase 1
A Phase I Study of GZR18 Injection in Healthy Subjects
Gan and Lee Pharmaceuticals, USA
Healthy volunteer
Aug 14, 2024